NASDAQ:ADIL

Adial Pharmaceuticals - ADIL Stock Forecast, Price & News

$0.35

-0.03 (-7.85%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.35
▼
$0.40
50-Day Range: $0.31
▼
$0.56
52-Week Range: $0.20
▼
$2.27

Volume: 167,638 shs
Average Volume: 1.65 million shs
Market Capitalization: $10.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Institutional Ownership

Adial Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 751.8% Upside
$3.00 Price Target
Short Interest: Healthy
1.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.69
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.56) to ($0.70) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

617th out of 1,005 stocks

Pharmaceutical Preparations Industry

293rd out of 486 stocks

3.3

Analyst's Opinion

Consensus Rating
Adial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Adial Pharmaceuticals has a forecasted upside of 751.8% from its current price of $0.35.
Amount of Analyst Coverage
Adial Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.34% of the outstanding shares of Adial Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adial Pharmaceuticals has recently increased by 37.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adial Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adial Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADIL.

3.2

News and Social Media Coverage

News Sentiment
Adial Pharmaceuticals has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Adial Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 7 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.22% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.42% of the stock of Adial Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Adial Pharmaceuticals are expected to decrease in the coming year, from ($0.56) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adial Pharmaceuticals is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adial Pharmaceuticals is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adial Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Stock News Headlines

March 21, 2023 | finance.yahoo.com

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

March 8, 2023 | finance.yahoo.com

Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 8, 2023 | finance.yahoo.com

Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

March 7, 2023 | msn.com

ADIL Soars after Positive Regulatory Update

March 6, 2023 | markets.businessinsider.com

Adial Pharma Surges 80% On Update Of AD04

March 6, 2023 | finance.yahoo.com

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

March 2, 2023 | finance.yahoo.com

Adial Pharmaceuticals Schedules Business Update Conference Call

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

February 28, 2023 | finance.yahoo.com

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?

February 27, 2023 | finance.yahoo.com

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

February 24, 2023 | finance.yahoo.com

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

February 21, 2023 | finance.yahoo.com

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

February 1, 2023 | finance.yahoo.com

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

November 16, 2022 | seekingalpha.com

Adial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06

October 4, 2022 | finance.yahoo.com

Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate

September 28, 2022 | benzinga.com

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain

September 26, 2022 | finance.yahoo.com

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

September 26, 2022 | finance.yahoo.com

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

September 22, 2022 | seekingalpha.com

ADIL Adial Pharmaceuticals, Inc.

September 6, 2022 | nasdaq.com

Adial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative Colitis

September 6, 2022 | finance.yahoo.com

Adial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate

September 6, 2022 | finance.yahoo.com

Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis

September 1, 2022 | finance.yahoo.com

Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher

August 29, 2022 | finance.yahoo.com

Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises

August 23, 2022 | seekingalpha.com

Adial Clinical Trial: A Fluff Or A Win?

August 18, 2022 | uk.investing.com

Adial Pharmaceuticals Provides Business Update, Reports Q2

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Company Calendar

Last Earnings: 8/11/2021
Today: 3/26/2023
Next Earnings (Estimated): 3/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADIL
CUSIP: N/A
CIK: 1513525
Web: www.adialpharma.com
Phone: (434) 422-9800
Fax: N/A
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +751.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -227.60%
Return on Assets: -156.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.10
Quick Ratio: 5.10

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 28,520,000
Free Float: 22,466,000
Market Cap: $10.04 million
Optionable: Not Optionable
Beta: 0.99

Key Executives

Cary J. Claiborne
President, Chief Executive Officer & Director

Joseph Truluck
Chief Financial Officer, Secretary & Treasurer

Bankole A. Johnson
Chief Medical Officer

Julien Dimastromatteo
Vice President-Research

Alex Lugovoy
Chief Business Officer

Key Competitors

View All Competitors

Institutional Ownership

Renaissance Technologies LLC
Bought 107,656 shares on 2/13/2023
Ownership: 0.974%

View All Institutional Transactions

ADIL Stock - Frequently Asked Questions

Should I buy or sell Adial Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings or view top-rated stocks.
What is Adial Pharmaceuticals' stock price forecast for 2023?: 2 equities research analysts have issued 12-month price targets for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 751.8% from the stock's current price.
View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts.
How have ADIL shares performed in 2023?: Adial Pharmaceuticals' stock was trading at $0.2150 at the beginning of the year. Since then, ADIL stock has increased by 63.8% and is now trading at $0.3522.
View the best growth stocks for 2023 here.
When is Adial Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ADIL earnings forecast.
How were Adial Pharmaceuticals' earnings last quarter?: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its earnings results on Wednesday, August, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.05.
What other stocks do shareholders of Adial Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?: (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.
What is Adial Pharmaceuticals' stock symbol?: Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."
Who are Adial Pharmaceuticals' major shareholders?: Adial Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.97%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends.
How do I buy shares of Adial Pharmaceuticals?: Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adial Pharmaceuticals' stock price today?: One share of ADIL stock can currently be purchased for approximately $0.35.
How much money does Adial Pharmaceuticals make?: Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $10.04 million. The company earns $-19,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How can I contact Adial Pharmaceuticals?: Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.

This page (NASDAQ:ADIL) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adial Pharmaceuticals - ADIL Stock Forecast, Price & News

Adial Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

ADIL Stock News Headlines

ADIL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ADIL Stock - Frequently Asked Questions

Overall MarketRank^™